Skip to main content

Advertisement

Table 1 Clinical, laboratory and procedural characteristics of the overall study population, and of patients with normal (< 6%) and elevated (≥ 6%) hemoglobin A1c (HbA1c)

From: Impaired glucose metabolism is associated with increased thrombin generation potential in patients undergoing angioplasty and stenting

Characteristics Overall (n = 315) HbA1c < 6% (n = 156)* HbA1c ≥ 6% (n = 145)* p
Demographics
 Age, years 66 (58–75) 65 (57–74) 66 (58–75) 0.4
 Male sex 205 (65.1) 103 (66) 95 (65.5) 0.9
 BMI, kg/m2 26.8 (24.2–29.7) 26.2 (23.4–28.7) 27.3 (25.1–29.7) 0.007
Medical history
 Hypertension 283 (89.8) 135 (86.5) 134 (92.4) 0.1
 Hypercholesterolemia 293 (93) 144 (92.3) 136 (93) 0.6
 Diabetes mellitus 102 (32.4) 11 (7.1) 85 (58.6) < 0.001
 Active smoking 132 (41.9) 76 (48.7) 53 (36.6) 0.03
Laboratory data
 HbA1c, %* 5.9 (5.6–6.5) 5.6 (5.4–5.8) 6.5 (6.1–7.2) <0.001
 Hematocrit, % 38.9 (36–42) 39.6 (36.4–42.6) 38.7 (35.4–41.4) 0.1
 White blood cell count, G/l 8.4 (6.9–10.4) 8.2 (6.8–10.3) 8.7 (7–10.6) 0.3
 Platelet count, G/l 208 (176–251) 207 (173–249) 210 (177–259) 0.6
 Serum creatinine, mg/dl 1 (0.9–1.2) 1 (0.9–1.1) 1 (0.9–1.3) 0.2
 High-sensitivity CRP, mg/dl 0.8 (0.3–1.8) 0.9 (0.3–2.1) 0.8 (0.3–1.7) 0.4
Procedure
 Stent implantation 315 (100) 156 (100) 145 (100) 1
 Number of stents/patient 1 (1–2) 1 (1–2) 1 (1–2) 0.3
Medication pre-intervention
 Clopidogrel 315 (100) 156 (100) 145 (100) 1
 Aspirin 315 (100) 156 (100) 145 (100) 1
 Statins 300 (95.2) 149 (95.5) 139 (95.9) 0.9
 ACE inhibitors/ARB 272 (86.3) 135 (86.5) 124 (85.5) 0.8
 Beta blockers 216 (68.6) 104 (66.7) 105 (72.4) 0.3
 Proton pump inhibitors 165 (52.4) 75 (48.1) 81 (55.9) 0.2
 Antidiabetic medication 96 (30.5) 11 (7.1) 79 (54.5) < 0.001
 Oral antidiabetic medication 77 (24.4) 8 (5.1) 67 (46.2) < 0.001
 Insulin 30 (9.5) 3 (1.9) 23 (15.9) < 0.001
  1. Continuous data are shown as median (interquartile range). Dichotomous data are shown as n (%)
  2. BMI body mass index, CRP c-reactive protein, ACE angiotensin converting enzyme, ARB angiotensin receptor blockers
  3. * HbA1c was only available for 301 patients (95.6%)